Associations of hashish use, different substances, and way of life decisions on anxiousness in medical hashish sufferers throughout 45 days

American Psychiatric Association. American Adults Express Increasing Anxiousness in Annual Poll; Stress and Sleep are Key Factors Impacting Mental Health. (2024). https://www.psychiatry.org/news-room/news-releases/annual-poll-adults-express-increasing-anxiousness

Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M. & Wittchen, H. U. Twelve-month and lifelong prevalence and lifelong morbid threat of tension and temper issues within the united States. Int. J. Methods Psychiatr Res. 21 (3), 169–184. (2012).

Google Scholar 

Stone, M. B. et al. Response to acute monotherapy for main depressive dysfunction in randomized, placebo managed trials submitted to the US meals and drug administration: particular person participant information evaluation. BMJ (Clinical Res. ed.). 378, e067606. (2022).

Google Scholar 

Kirsch, I., Moore, T. J., Scoboria, A. & Nicholls, S. S. The emperor’s new medication: An evaluation of antidepressant remedy information submitted to the U.S. Food and Drug Administration. Prev. Treat. 5 (1). (2002).

Kirsch, I. et al. Initial severity and antidepressant advantages: a meta-analysis of knowledge submitted to the meals and drug administration. PLoS Med. 5 (2), e45. (2008).

Google Scholar 

Edinoff, A. N. et al. Benzodiazepines: Uses, Dangers, and scientific concerns. Neurol. Int. 13 (4), 594–607. (2021).

Google Scholar 

Sales, A. J. et al. Cannabidiol induces speedy and sustained antidepressant-like results via elevated BDNF signaling and synaptogenesis within the prefrontal cortex. Mol. Neurobiol. 56 (2), 1070–1081. (2019).

Google Scholar 

Corroon, J. M. Jr, Mischley, L. Okay. & Sexton, M. Cannabis as an alternative choice to pharmaceuticals – a cross-sectional research. J. Pain Res. 10, 989–998. (2017).

Google Scholar 

Han, Okay., Wang, J. Y., Wang, P. Y. & Peng, Y. C. Therapeutic potential of Cannabidiol (CBD) in anxiousness issues: A scientific evaluate and meta-analysis. Psychiatry Res. 339, 116049. (2024).

Google Scholar 

Sharpe, L., Sinclair, J., Kramer, A., de Manincor, M. & Sarris, J. Cannabis, a trigger for anxiousness? A important appraisal of the anxiogenic and anxiolytic properties. J. Transl Med. 18 (1), 374. (2020).

Google Scholar 

Lichenstein, S. D. & THC CBD, and anxiousness: A evaluate of latest findings on the anxiolytic and anxiogenic results of hashish’ major cannabinoids. Curr. Addict. Rep. 9 (4), 473–485. (2022).

Google Scholar 

Kedzior, Okay. Okay. & Laeber, L. T. A constructive affiliation between anxiousness issues and hashish use or hashish use issues within the common inhabitants–a meta-analysis of 31 research. BMC Psychiatry. 14, 136. (2014).

Google Scholar 

Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M. & Firth, J. Medicinal hashish for psychiatric issues: a clinically-focused systematic evaluate. BMC Psychiatry. 20 (1), 24. (2020).

Google Scholar 

Danielsson, A. Okay., Lundin, A., Agardh, E., Allebeck, P. & Forsell, Y. Cannabis use, melancholy and anxiousness: A 3-year potential population-based research. J. Affect. Disord. 193, 103–108. (2016).

Google Scholar 

Beletsky, A., Liu, C., Lochte, B., Samuel, N. & Grant, I. Cannabis and Anxiety: A Critical Review. Med. Cannabis Cannabinoids. 7(1), 19–30 (2016). (2024) https://doi.org/10.1159/000534855Cuttler

Elsaid, S. et al. Expectancies of the consequences of hashish use in people with social anxiousness dysfunction (SAD). Brain Sci. 14 (3), 246. (2024).

Google Scholar 

Hayaki, J. et al. Expectancies and marijuana use frequency and severity amongst younger females. Addict. Behav. 35 (11), 995–1000. (2010).

Google Scholar 

Mueller, J. et al. Effects of hashish expectations upon present anxiousness and depressive signs amongst girls with post-traumatic stress dysfunction. Cannabis Clinical Outcomes Research Conference: Abstract (2024). Retrieved from: https://ccorc.mmjoutcomes.org/2024-abstract-gallery/effects-of-cannabis-expectancies-upon-current-anxiety-and-depressive-symptoms-among-women-with-post-traumatic-stress-disorder.html

Rosenthal, M. S. & Pipitone, R. N. Demographics, perceptions, and use of medical marijuana amongst sufferers in Florida. Med. Cannabis Cannabinoids. 4, 13–20. (2021).

Google Scholar 

Kimless, I. et al. An observational Cross-Sectional survey exploring the indications for and responses to medical marijuana use in licensed sufferers in Pennsylvania. J. Prim. Care Community Health. 13, 1–10. (2022).

Google Scholar 

Sexton, M., Cuttler, C., Finnell, J. & Mischley, L. A cross-sectional survey of medical hashish customers: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 1, 131–138. (2016).

Google Scholar 

Webb, C. W. & Webb, S. M. Therapeutic advantages of hashish: a affected person survey. Hawai’i J. Med. Public. Health. 73 (4), 109–111 (2014).

Google Scholar 

Hyman, S. M. & Sinha, R. Stress-related components in hashish use and misuse: implications for prevention and therapy. J. Subst. Abuse Treat. 36, 400–413. (2009).

Google Scholar 

Johnston, L. D. & O’Malley, P. M. Why do the nations’ college students use medication and alcohol? Self-reported causes from 9 National surveys. J. Drug Issues. 16, 29–66. (1986).

Google Scholar 

Martin, E. L. et al. Antidepressant and anxiolytic results of medicinal hashish use in an observational trial. Front. Psychiatry. 12, 729800. (2021).

Google Scholar 

Berger, M., Amminger, G. P. & McGregor, I. S. Medicinal hashish for the therapy of tension issues. Aust J. Gen. Pract. 51 (8), 586–592. (2022).

Google Scholar 

Singh, B. et al. Effectiveness of bodily exercise interventions for enhancing melancholy, anxiousness, and misery: an outline of systematic evaluations. Br. J. Sports Med. 57, 1203–1209. (2023).

Google Scholar 

Hoge, E. A., Bui, E. & Mete, M. Mindfulness-based stress discount vs Escitalopram for the therapy of adults with anxiousness. JAMA Psychiatry. 80 (1), 13–21. (2023).

Google Scholar 

Cuttler, C., Spradlin, A. & McLaughlin, R. J. A naturalistic examination of the perceived results of hashish on unfavorable have an effect on. J. Affect. Disord. 235, 198–205. (2018).

Google Scholar 

Pipitone, R. N. et al. Using smartphone expertise to trace real-time modifications in anxiousness/melancholy symptomatology amongst Florida hashish customers. Cannabis 7 (2), 123–134. (2024).

Google Scholar 

Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, Okay. & Hall, B. Patient-reported symptom reduction following medical hashish consumption. Front. Pharmacol. 9, 916. (2018).

Google Scholar 

Cuttler, C., Mischley, L. & Sexton, M. Sex variations in hashish use and results: a cross-sectional survey of hashish customers. Cannabis Cannabinoid Res. 1, 166–175. (2016).

Google Scholar 

Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, Okay. & Hall, B. The affiliation between hashish product traits and symptom reduction. Sci. Rep. 9 (1), 2712. (2019).

Google Scholar 

Kelley, M. D., Obaid, M., Miller, E. M., Bowie, M. & Hetter, Z. S. Observational evaluation of the affect of medical marijuana use on high quality of life in sufferers. Med. Cannabis Cannabinoids. 7, 44–55. (2024).

Google Scholar 

Hamilton, M. The evaluation of tension States by score. Br. J. Med. Psychol. 32, 50–55 (1959).

Google Scholar 

Matza, L. S., Morlock, R., Sexton, C., Malley, Okay. & Feltner, D. Identifying HAM-A cutoffs for gentle, reasonable, and extreme generalized anxiousness dysfunction. Int. J. Methods Psychiatr Res. 19 (4), 223–232. (2010).

Google Scholar 

The jamovi mission. jamovi (Version 2.5) [Computer Software]. (2024). Retrieved from https://www.jamovi.org

Westfall, J., Kenny, D. A. & Judd, C. M. Statistical energy and optimum design in experiments wherein samples of individuals reply to samples of stimuli. J. Exp. Psychol. Gen. 143 (5), 2020–2045. (2014).

Google Scholar 

Wayne, R. Evaluating remedy results exterior of scientific trials: New-User designs. Am. J. Epidemiol. 158 (9), 915–920. (2003).

Google Scholar 

Her, Q. L., Rouette, J., Young, J. C., Webster-Clark, M. & Tazare, J. Core ideas in pharmacoepidemiology: New-User designs. Pharmacoepidemiol Drug Saf. 33 (12), e70048. (2024).

Google Scholar 

McLean, C. P., Asnaani, A., Litz, B. T. & Hofmann, S. G. Gender variations in anxiousness issues: Prevalence, course of sickness, comorbidity and burden of sickness. J. Psychiatr Res. 45 (8), 1027–1035. (2011).

Google Scholar 

Colizzi, M. & Bhattacharyya, S. Cannabis use and the event of tolerance: a scientific evaluate of human proof. Neurosci. Biobehav Rev. 93, 1–25. (2018).

Google Scholar 

Russell, C., Rueda, S., Room, R., Tyndall, M. & Fischer, B. Routes of administration for hashish use – fundamental prevalence and associated well being outcomes: A scoping evaluate and synthesis. Int. J. Drug Policy. 52, 87–96. (2018).

Google Scholar 

Kritikos, A. F., Graham, M., Hodgkin, D. & Pacula, R. L. Medical hashish dosing trajectories of sufferers: proof from gross sales information. Clin. Ther. S0149-2918 (2024). (24)00265-0.

Childs, E., Lutz, J. A. & de Wit, H. Dose-related results of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend. 177, 136–144. (2017).

Google Scholar 

Yang, Okay. H. et al. Cannabis: an rising therapy for frequent signs in older adults. J. Am. Geriatr. Soc. 69 (1), 91–97. (2021).

Google Scholar 

Spinella, T. C., Stewart, S. H., Naugler, J., Yakovenko, I. & Barrett, S. P. Evaluating Cannabidiol (CBD) expectancy results on acute stress and anxiousness in wholesome adults: a randomized crossover research. Psychopharmacol 238 (7), 1965–1977. (2021).

Google Scholar 

Rosenthal, M. S. Drugs: Mind, Body, and Society (2e)Oxford University Press, (2022).

Degenhardt, L. et al. Adolescent hashish use and psychological well being. Addict 108, 124–133. (2013).

Google Scholar 

Van Ameringen, M., Zhang, J., Patterson, B. & Turna, J. The position of hashish in treating anxiousness: an replace. Curr. Opin. Psychiatry. 33 (1), 1–7. (2020).

Google Scholar